TTX-030 *

TTX-030 is a monoclonal antibody that inhibits the activity of CD39.

Tizona Therapeutics is leading the development of TTX-030 through the  completion of Phase 1b studies, after which AbbVie has an exclusive option to lead global development and commercial activities. Tizona retains an option to co-develop and co-promote TTX-030 in the U.S.

Type of Molecule

Biologic

Target

CD39

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Solid Tumors n/a
Phase 1